What You Ought to Know:
– myTomorrows, a well being know-how firm that connects sufferers with all potential pre-approval remedies, at present introduced the shut of a $29 million financing with Avego. Avego’s progress fairness funding will gasoline the worldwide enlargement of myTomorrows’ built-in pharma options to make rising remedies extra equitable and accessible for sufferers globally.
– With greater than 300 million sufferers worldwide dealing with circumstances with out authorised remedy choices, and over 10,000 therapies presently in improvement or awaiting approval – myTomorrows is addressing one among healthcare’s most pressing challenges: bridging the hole between scientific development and affected person entry to pre-approval remedies, which embody medical trials and expanded entry applications (EAPs).
myTomorrows Expands World AI Platform to Speed up Affected person Entry to Pre-Approval Remedies
myTomorrows is redefining how sufferers and physicians entry investigational therapies by bridging the hole between medical improvement and real-world care. The worldwide HealthTech firm operates a unified, multi-stakeholder platform that connects sufferers, physicians, trial websites, and BioPharma companions—simplifying entry to pre-approval remedies by way of the ability of AI and skilled human navigation. By bringing transparency, coordination, and perception to the remedy discovery course of, myTomorrows is accelerating international entry to progressive therapies whereas advancing data-driven drug improvement.
The newest funding will gasoline the corporate’s worldwide enlargement and additional improve its AI-driven international platform—deepening integration with BioPharma companions to shorten medical improvement timelines, enrich real-world proof era, and strengthen regulatory perception. “This funding marks a pivotal step in our journey to offer each affected person, irrespective of the place they stay, a good shot at tomorrow’s therapies,” stated Michel van Harten, CEO of myTomorrows. “Avego’s deep life sciences experience, particularly in BioPharma, will probably be instrumental as we scale our platform and broaden our international affect.”
Immediately, myTomorrows operates the world’s most complete AI-powered platform for pre-approval remedies, having already supported greater than 16,900 sufferers throughout 133 international locations. The platform empowers sufferers and clinicians by way of skilled steerage, personalised remedy matching, and seamless entry to each medical trials and expanded entry applications. For BioPharma companions, it gives end-to-end companies in trial recruitment, expanded entry administration, and real-world information seize, whereas trial websites profit from unified referral programs with real-time monitoring and enhanced visibility.
By connecting each stakeholder within the remedy ecosystem, myTomorrows is laying the muse for a brand new period of worldwide healthcare entry—one outlined by AI-enabled precision, adaptive regulation, and empowered sufferers. Embedded throughout well being programs worldwide, its platform gives unbiased, actionable pathways to rising therapies, guaranteeing that medical breakthroughs attain those that want them most—precisely when it issues.
